1. Diagnose og første behandling af lungekræft
Patient Lu blev diagnosticeret med lungeadenokarcinom og lymfeknudemetastase den 26. august 2005. En venstre nedre lobektomi blev udført den 22. september 2005. Carboplatin kombineret med taxotere blev brugt 4 gange efter operationen. Den 3. august 2007, på grund af pleural effusion, blev diagnosen bekræftet som værende tilbagevendende, og hun blev behandlet med Tarceva (antallet af cyklusser er ukendt). Den 8. januar 2008 blev kræftfremskridtet fundet ved genundersøgelsen, og derefter blev Tarceva-behandlingen stoppet og Libita-behandlingen startet i 16 cyklusser. Samtidig blev vertebral hoftemetastase fundet, og der blev udført 4 cyklusser af Zetai.
2. Første gang at deltage i kliniske forsøg, er tilstanden under kontrol.
In July 2010, Mr. Lu reexamined a large area of brain metastasis and found dozens of small lesions in the brain. He also tested positive for the EML4-ALK fusion gene at the University of Chicago School of Medicine. The whole brain radiation therapy was then used to control the lesions, and the second phase of crizotinib drug trial was started at St. Louis University Hospital. During the treatment, the condition was stably controlled, but a re-examination in May 2012 found that the cancer had progressed slightly, and the tumor was suspected to be resistant to crizotinib. He stopped crizotinib on July 18, 2012.
3. I det andet kliniske forsøg forsvandt tumoren tydeligvis.
On August 6, 2012, Mr. Lu participated in the AP26113 drug kliniske forsøg at Denver Hospital. In October, the PET examination showed that the tumor disappeared and the svulst i hjernen decreased and became large.
4. Oplev sjældne genmutationer og glæd dig til at deltage i nye kliniske forsøg
Genundersøgelse i juli 2014 viste PET for hele kroppen: Hjernelæsioner var grundlæggende stabile, og brystet havde tydelige fremskridt. Den 12. maj 2014 blev de mistænkte anti-AP26113 lymfe (3 celler, største 1.1 cm) dyrkede cellelinjer udført på Massachusetts General Hospital og fortsatte med at tage AP26113.
In August 2014, the doctor called and found that Mr. Lu’s new tumor tissue sequencing detected rare or unseen mutations. This mutation was only reported in ALK-positive children’s neuroblastom and inflammatory myofibroblastoma. Previous research reports and medical evidence have shown that crizotinib cannot cope with the resistant neuroblastoma caused by this mutation. New genetic test results indicate that Mr. Lu may need to find new drugs for treatment.
On December 8, 2014, after a doctor’s analysis and decision, Mr. Lu was approved to increase the dosage of AP26113 and changed it to 240 mg per day, so the drug replacement plan was temporarily delayed. After observing the efficacy, he decided whether to change the drug and participate in other clinical trials. The patient learned through the hospital that NIVOLUMAB monoclonal antibody immunterapi phase 3/4 drug test is recruiting lung cancer patients on a large scale, and Mr. Lu is fully confident of the future anti-cancer.
